{
    "relation": [
        [
            "",
            "Lisinopril/P-placebo",
            "L-placebo/Pravastatin",
            "Lisinopril/Pravastatin",
            "L-placebo/P-placebo",
            "Total"
        ],
        [
            "Description",
            "Lisinopril 10mg and placebo (matched to pravastatin) once daily",
            "Placebo pill (matched to lisinopril) and Pravastatin 20mg once daily",
            "Lisinopril 10mg and Pravastatin 20mg once daily",
            "Placebo pill (matched to pravastatin) and placebo pill (matched to lisinopril) once daily",
            "Total of all reporting groups"
        ]
    ],
    "pageTitle": "Cardiovascular Prevention for Persons With HIV - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00982189?sect=X7015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 6,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987171.38/warc/CC-MAIN-20150728002307-00272-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 873050983,
    "recordOffset": 873040639,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Pravastatin Drug: Lisinopril Interventions: HIV Infection Cardiovascular Disease Risk Conditions: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Factorial\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Prevention Study Design: Interventional Study Type: Results First Received: January 16, 2012 \u00a0",
    "textAfterTable": "\u00a0 \u00a0 Lisinopril/P-placebo \u00a0 \u00a0 L-placebo/Pravastatin \u00a0 \u00a0 Lisinopril/Pravastatin \u00a0 \u00a0 L-placebo/P-placebo \u00a0 STARTED \u00a0 \u00a0 10 \u00a0 \u00a0 9 \u00a0 \u00a0 9 \u00a0 \u00a0 9 \u00a0 COMPLETED \u00a0 \u00a0 10 \u00a0 \u00a0 9 \u00a0 \u00a0 9 \u00a0 \u00a0 9 \u00a0 NOT COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}